LncRNA MITA1 promotes gefitinib resistance by inducing autophagy in lung cancer cells.

Lung cancer is a major health challenge worldwide. Gefitinib, a tyrosine kinase inhibitor (TKI), is the common therapeutic drug used in advanced non-small-cell lung cancer (NSCLC). However, it is eventually bound to face the problem of acquired drug resistance.

Cytochrome P450 1A1 exon 7 polymorphism and susceptibility to lung cancer in the Chinese population: an updated meta-analysis and review.

Background: Although many epidemiologic studies have investigated the cytochrome P450 1A1 (CYP1A1) exon 7 gene polymorphism and its association with lung cancer (LC), definitive conclusions cannot be drawn.

Objective: To clarify the effects of CYP1A1 exon 7 polymorphism on the risk of LC, an updated meta-analysis was performed in the Chinese population.

Methods: Related studies were identified from PubMed, Springer Link, Ovid, the Chinese Wanfang Data Knowledge Service Platform, Chinese National Knowledge Infrastructure (CNKI), and the Chinese Biology Medicine (CBM) databases until October 2014.

A preliminary analysis of non-small cell lung cancer biomarkers in serum.

Objective: To identify potential serum biomarkers that could be used to discriminate lung cancers from normal.

Methods: Proteomic spectra of twenty-eight serum samples from patients with non-small cell lung cancer and twelve from normal individuals were generated by SELDI (Surfaced Enhanced Laser Desorption/Ionization) Mass Spectrometry. Anion-exchange columns were used to fractionate the sera into 6 designated pH groups.